Friday 20 March 2026
Internal Reference Number: FOI_9167
Date Request Received: 14/01/2026 00:00:00
Date Request Replied To: 04/02/2026 00:00:00
This response was sent via: By Email
Request Summary: Acute Myeloid Leukaemia (AML) Patients
Request Category: Companies
| Question Number 1: FOI Request: Acute Myeloid Leukaemia (AML) Patients How many patients have been diagnosed with Acute Myeloid Leukaemia (AML) at your Trust in the last 12 months a. Of these patients how many are refractory/relapsed (R/R)? b. How many of the R/R patients were FLT3 positive? | |
| Answer To Question 1: Q1. <=5 patients diagnosed with AML. | |
| Question Number 2: How many patients have been treated for AML in the latest 12 months with the following treatments • Venetoclax with azacitidine • Midostaurin • Quizartinib • Gemtuzumab • Ivosidenib with azacitidine • Liposomal cytarabine–daunorubicin • Oral azacitidine • Gilteritinib • Palliative care • Enrolled in a clinical trial | |
| Answer To Question 2: Please note, we are unable to differentiate between Venetoclax with azacitidine and Ivosidenib with azacitidine AZACITIDINE = 7 MIDOSTAURIN < = 5 Palliative care < = 5 Enrolled in a clinical trail <=5 No other results. | |
| Question Number 3: How many relapsed/refractory patients have been treated for AML in the last 12 months with the following treatments (This question relates to treatments administered to relapsed/refractory AML patients in clinical practice, regardless of licence status or funding route (including any off-label use). • Venetoclax with azacitidine • Midostaurin • Quizartinib • Gemtuzumab • Ivosidenib with azacitidine • Liposomal cytarabine–daunorubicin • Oral azacitidine • Gilteritinib • Palliative care • Enrolled in a clinical trial | |
| Answer To Question 3: Fewer than 5 patients with relapsed/refractory AML have been enrolled in a clinical trial Venetoclax with azacitidine <5 • Midostaurin 0 • Quizartinib 0 • Gemtuzumab 0 • Ivosidenib with azacitidine0 • Liposomal cytarabine–daunorubicin0 • Oral azacitidine 0 • Gilteritinib 0 • Palliative care 0 • Enrolled in a clinical trial- 0 | |
| Question Number 4: Of your AML patient how many were tested as below in the last 12 months • Received an FLT3 mutation test when they were diagnosed • Received an FLT3 mutation test when their disease relapsed • Received an FLT3 mutation test when their disease became refractory | |
| Answer To Question 4: Received an FLT3 mutation test when they were diagnosed <5 • Received an FLT3 mutation test when their disease relapsed 0 • Received an FLT3 mutation test when their disease became refractory 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
